The Horrifying Endgame in Ukraine

"Worst-Case Scenario": Novo Nordisk Plunges After Next-Gen Obesity Drug Falls Short Of Lilly Rival Shares of Novo Nordisk A/S plummeted again on Monday after the company reported trial results showing its next-generation obesity shot, CagriSema, delivered 20.2% weight loss at 84 weeks, compared to 23.6% for Eli Lilly & Co.’s tirzepatide (Zepbound). Bloomberg Intelligence analyst Michael Shah explained, "This outcome is the worst-case scenario for Novo and heightens the need for M&A with Novo’s other GLP-1/Amylin drug." Shares of Novo in Copenhagen plunged as much as 16.5%, breaking below a support level...

Hindenburg Alarm: Another Rotation Or Worse? Via RealInvestmentAdvice.com, In early November, we sounded the alarm about a recent Hindenburg Omen. Per the Commentary’s summary: Bottom line: market breadth is horrendous and will likely lead to a rotation favoring out-of-favor sectors and stocks. Thus, it’s not surprising that the Hindenburg Omen was triggered. If we continue to see more of these Omens, the threat of a drawdown grows. At the time, Mega-Cap stocks were grossly outperforming the market, while many sectors lagged the market. Since that Hindenburg Alarm, our expectations have come to fruition. We have, in fact,...

A 27-year-old Palestinian woman was killed by Israeli fire in Beith Lahia, northern Gaza, on Sunday, the Palestinian news agency WAFA reported, as IDF attacks continue across the Strip despite the US-backed ceasefire deal. The woman, Basma Aram Banat, succumbed to gunshot wounds two hours after she was shot. WAFA also reported that Israeli shelling […]